title: Effect of β-tricalcium phosphate coated with zoledronic acid on human osteoblasts and human osteoclasts in vitro.
abstract: The combination of a bone graft material with bisphosphonates (BPs) might be advantageous for an optimal balance of material resorption and stimulation of bone formation. This study investigated the effect of β-tricalcium phosphate (β-TCP) bone grafts coated with zoledronic acid (ZOL) on osteoblast-like cells and osteoclast-like cells (OLC). As a drug carrier, the polymer poly(D,L-lactide) was used and three different concentrations of ZOL were tested. β-TCP coated with ZOL stimulated the production of osteocalcin (OC), osteoprotegerin, and sRANKL in osteoblast-like cells. The polymer coating alone caused a significant increase in collagen type 1 and OC production. OLC viability was inhibited and the tartrate-resistant acidic phosphatase isoform-5b was significantly decreased after cultivation on polymer-coated β-TCP for 12 days. The three different concentrations of ZOL decreased cell viability and no TRAPiso-5b was detectable, indicating a strong reduction of the TRAPiso-5b after 12 days in culture. After 21 days in culture, only the higher ZOL concentrations significantly reduced cell viability and TRAPiso-5b. The results of this study show that coating of β-TCP with ZOL has stimulating effects on osteoblast-like cells. Additionally, an inhibition of osteoclasts was seen. The combination of this bone grafting material with BPs might, therefore, be effective in the treatment of large bone defects.
authors.affiliation: Berlin-Brandenburg Center for Regenerative Therapies, Julius Wolff Institut, Charité - Universitätsmedizin Berlin, Berlin, Germany.
authors.forename: A
authors.initials: A
authors.lastname: Kadow-Romacker
authors.forename: S
authors.initials: S
authors.lastname: Greiner
authors.forename: G
authors.initials: G
authors.lastname: Schmidmaier
authors.forename: B
authors.initials: B
authors.lastname: Wildemann
mesh_terms: D050071:Bone Density Conservation Agents / Q000737:chemistry / Q000494:pharmacology*; D002130:Calcium Phosphates / Q000737:chemistry / Q000494:pharmacology*; D002478:Cells, Cultured; D004164:Diphosphonates / Q000737:chemistry / Q000494:pharmacology*; D006801:Humans; D007093:Imidazoles / Q000737:chemistry / Q000494:pharmacology*; D066298:In Vitro Techniques; D015675:Osteocalcin / Q000096:biosynthesis; D010010:Osteoclasts / Q000166:cytology / Q000187:drug effects* / Q000378:metabolism; D053244:Osteoprotegerin / Q000096:biosynthesis; D053245:RANK Ligand / Q000096:biosynthesis; D000077211:Zoledronic Acid
chemical_list: D050071:Bone Density Conservation Agents; D002130:Calcium Phosphates; D004164:Diphosphonates; D007093:Imidazoles; D053244:Osteoprotegerin; D053245:RANK Ligand; C505688:TNFSF11 protein, human; C485817:beta-tricalcium phosphate; D015675:Osteocalcin; D000077211:Zoledronic Acid